Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) said nipocalimab received U.S. FDA Fast Track designation for adults with systemic lupus erythematosus (SLE) on March 3, 2026. The designation reflects unmet need and may accelerate review. A Phase 2b (JASMINE) showed reduced lupus disease activity and steroid-sparing potential; Phase 3 (GARDENIA) enrollment is underway.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call to discuss first-quarter results at 8:30 a.m. ET on Tuesday, April 14, 2026. Joaquin Duato, CEO; Joseph Wolk, CFO; and Darren Snellgrove, VP Investor Relations, will host and additional executives will join the Q&A.
The webcast and presentation materials will be available at www.investor.jnj.com. A replay will be posted about three hours after the call and remain available until approximately 12:00 a.m. on April 28, 2026. U.S. dial-in numbers and international numbers are provided for live participation and replay; the replay conference ID is 13759017. The press release will be available at about 6:45 a.m. ET on the morning of the call.
Johnson & Johnson (NYSE:JNJ) reported preliminary Phase 1b results showing the bispecific T-cell engager pasritamig plus docetaxel produced deep, durable PSA reductions and a safety profile consistent with docetaxel alone. Among 51 patients, PSA declines ≥50% occurred in 64.7% overall and 75.0% of taxane-naïve patients. No cytokine release syndrome or treatment-related deaths were observed. The program is advancing into Phase 3 studies, with two trials ongoing and regulatory designations in China and the U.S.
Johnson & Johnson (NYSE: JNJ) submitted an sBLA to the FDA on Feb 24, 2026, seeking approval of IMAAVY (nipocalimab) as the first treatment for warm autoimmune hemolytic anemia (wAIHA).
Phase 2/3 ENERGY showed a rapid, durable hemoglobin response and improved fatigue versus placebo; IMAAVY was generally well tolerated. Full ENERGY results are forthcoming.
Johnson & Johnson (NYSE: JNJ) reported long-term QUASAR LTE results showing sustained TREMFYA (guselkumab) benefit through Week 140 in adults with moderately to severely active ulcerative colitis. At Week 140, 80.8% were in clinical remission, 78.6% achieved histo-endoscopic mucosal improvement, and 53.6% reached endoscopic remission.
About 89% of eligible participants completed treatment through Week 140, 87.5% of Week 44 remitters stayed in remission through Week 140, efficacy held regardless of prior biologic/JAK history, and no new safety concerns were observed.
Johnson & Johnson (NYSE:JNJ) reported Phase 1b/2 OrigAMI-4 results showing first-line subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus pembrolizumab produced a 56% confirmed overall response rate (22/39) and a 10% complete response rate in PD-L1-positive, HPV-unrelated recurrent or metastatic HNSCC.
Median follow-up was 10.4 months; median PFS was 7.7 months and median OS was not estimable. Safety matched known profiles with no new signals.
Johnson & Johnson (NYSE: JNJ) announced a more than $1 billion investment in a next‑generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The site is expected to create >4,000 construction jobs and >500 biomanufacturing jobs and is part of a $55 billion U.S. investment through early 2029.
This expands JNJ’s Pennsylvania footprint, supporting its roughly $10 billion annual economic impact and adding to ten statewide facilities totaling more than 2 million square feet.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA granted Breakthrough Therapy Designation on Feb 18, 2026 for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as monotherapy for adults with recurrent or metastatic, HPV-unrelated head and neck squamous cell carcinoma after platinum and PD-1/PD-L1 therapy.
The designation is based on Phase 1b/2 OrigAMI-4 data showing rapid, durable responses in a heavily pretreated population; a Phase 3 OrigAMI-5 trial is ongoing.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combined with oral LAZCLUZE for first-line EGFR-mutated advanced NSCLC, available as early as Week 5.
The approval preserves established efficacy and safety versus the bi-weekly subcutaneous schedule, shows pharmacokinetic comparability to prior IV and SC regimens, and reports a fivefold reduction in administration-related reactions versus historical IV delivery.
Summary not available.